nnrti

(Iso)-Fosdevirine ( (Iso)-GSK2248761) is a selective and potent non-nucleoside reverse transcriptase (NNRTI) inhibitor with anti-HIV activity for the study of neurological disorders such as late-onset epilepsy.

IQP-0528 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that has potential for the treatment of HIV infection by blocking viral entry and shows antiviral activity as a microbicidal gel. . IQP-0528 showed inhibition of both HIV-1 and HIV-2, with an EC50 of 0.2 nM for HIV-1 and 100 nM for HIV-2.

UC-781 (NSC-675186) is a potent and selective inhibitor of human immunodeficiency virus HIV-1 non-nucleoside reverse transcriptase (NNRTI) I with a C50 value of 5 nM.UC-781 exhibits both antiviral activity and drug resistance.UC-781 is in a stable state, and is unaffected by lower pH or varying temperatures.

Fosdevirine (GSK2248761) is a selective and potent non-nucleoside reverse transcriptase (NNRTI) inhibitor with anti-HIV activity for the study of neurological related disorders such as late-onset epilepsy.

NNRTIs-IN-1 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with notable anti-resistance efficacy, effectively inhibiting both the wild-type HIV-1 and five mutant strains at EC50 values within the nanomolar range. This compound also exhibits favorable pharmacokinetic properties [1].

NNRTIs-IN-3 (compound 8) is an HIV-1 non-nucleoside reverse transcriptase inhibitor, displaying potent efficacy with an EC50 value of 0.01 µM [1].

Rilpivirine (R278474) is a diarylpyrimidine derivative and reverse transcriptase inhibitor with antiviral activity against HIV-1 that is used in the treatment of HIV infections.

Lersivirine (UK-453061)(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy.

RO-0335 is a potent diphenylether nonnucleoside reverse transcriptase inhibitor. RO-0335 inhibits Wt HIV-1 (IC50 = 1.1 nM) and retained activity (IC50< 100 nM) against 92% of a large number of NNRTI-resistant clinical isolates.

A 75925, a nonnucleoside reverse transcriptase inhibitors (NNRTI), works to inhibit HIV-1 replication.

Nevirapine quinone methide is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. Etravirine D4 is the deuterium labeled Etravirine.

AIC-292 is a potent reverse transcriptase inhibitor with well tolerated in different cell lines. In addition, activity of AIC292 could be demonstrated against a broad panel of wild-type HIV-1 group. AIC292 also retained activity against viruses harboring

Bavtavirine, a potent non-nucleoside reverse transcriptase inhibitor (NNRTI), forms an integral component of the highly active antiretroviral therapy (HAART) regimen for HIV disease research [1].

Nevirapine hemihydrate is a non-nucleoside reverse transcriptase inhibitor (NNRTI) studied for potential treatment of HIV-1 infection and AIDS.

CP-94707 is a new inhibitor of nonnucleoside reverse transcriptase (NNRTI).

Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Delavirdine is part of Highly Active Antiretroviral Therapy (HAART), which can be used to treat human immunodeficiency virus (HIV) type 1.

NNRT-IN-2 (compound 7w) is an orally administered non-nucleoside reverse transcriptase inhibitor (NNRTI) that effectively suppresses both wild-type HIV-1 and various mutant strains. It inhibits HIV-1 reverse transcriptase with an EC 50 value of 22 nM. Additionally, NNRT-IN-2 exhibits insensitivity to CYP and hERG, demonstrating favorable safety and pharmacokinetic profiles [1].

HIV-1 Inhibitor-57 (Compound 12g) is an antiviral agent that potently inhibits both wild-type and five common NNRTI-resistant strains of HIV-1, exhibiting EC50 values between 0.024 and 0.0010 μM. It achieves this efficacy by forming supplementary interactions with residues surrounding the binding site in the HIV-1 reverse transcriptase (RT) [1].

CI-39, a natural antiviral product, serves as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting wild type HIV-1. It exhibits an effective concentration (EC50) of 3.40 µM against the virus, while its cytotoxic concentration (CC50) exceeds 30 µM. This compound notably impedes HIV-1 reverse transcriptase (RT) DNA polymerase and ribonuclease H activities[1].

HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme, showing strong antiretroviral activity with an EC50 value of 40 nM and an IC50 value of 80 nM. Moreover, it demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC50 values from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].

HIV-1 inhibitor-40 (Compound 4ab), an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 1.9 nM, exhibits no significant acute toxicity in vivo and functions as a highly sensitive inhibitor of the orexin receptor antagonist CYP.

Nevirapine dimer is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

HIV-1 inhibitor-19 is a potent inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRTI) that targets L100I, K103N, and V106A F227L mutant strains with EC50s of 7.3 nM, 9.2 nM, and 21.0 nM, respectively.

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

HIV-1 inhibitor-48 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and exhibits anti-HIV-1 activity .

HIV-1 inhibitor-50 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets HIV-1 reverse transcriptase (IC50 = 50 nM). HIV-1 inhibitor-50 shows significant antiviral activity, with EC50s of 2.22-53.3nM against HIV-1 IIIB and its mutant strains.

Delavirdine mesylate (BHAP-U 90152 (mesylate)) is a non-nucleoside reverse transcriptase inhibitor (NNRTI).

HIV-1 Inhibitor-58 (Compound 10c) is a non-nucleoside reverse transcriptase inhibitor with broad-spectrum antiviral properties, effective against both wild-type strain IIIB and NNRTI-resistant strains like K103N and E138K in MT-4 cells at an EC50 of less than 50 nM. Additionally, it inhibits CYP2C9 and CYP2C19 with IC50 values of 2.06 μM and 1.91 μM, respectively. This compound is utilized in HIV infection research [1].

GSK 224876 is a novel next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI). It has activity against efavirenz-resistant strains in the treatment of treatment-naive HIV-1-infected subjects.

K-5a2 is a novel human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI).

HIV-1 inhibitor-8 is a potent, orally active, low toxicity HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-8 is capable of acting on WT HIV-1 reverse transcriptase (IC50: 0.081 μM). HIV-1 inhibitor-8 exhibited potent antiviral effects against various HIV-1 strains with EC50 values of 4.44-54.5 nM.

Etravirine (R165335) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT.